Disclosed herein is the use of a first population of allogeneic T-cells recognizing a first EBV epitope, and a second allogeneic population recognizing a second EBV epitope in the treatment of EBV-associated disorders. Also disclosed is the use of a population of allogeneic T-cells recognizing an EBV antigen in combination with a further therapeutic agent such as an immunotherapeutic agent, a MAPK, BET or MEK. pathway inhibitor for treating EBV-associated disease.

Disclosed herein is the use of a first population of allogeneic T-cells recognizing a first EBV epitope, and a second allogeneic population recognizing a second EBV epitope in the treatment of EBV-associated disorders. Also disclosed is the use of a population of allogeneic T-cells recognizing an EBV antigen in combination with a further therapeutic agent such as an immunotherapeutic agent, a MAPK, BET or MEK. pathway inhibitor for treating EBV-associated disease.

Provided is a pharmaceutical composition for treating and/or preventing fatty liver disease, particularly nonalcoholic fatty liver disease, the pharmaceutical composition having an excellent ACC2-selective inhibitory action and having no side effects such as an increase in plasma triglyceride or a decrease in platelet concentration.

A pharmaceutical composition for treating and/or preventing fatty liver disease, the pharmaceutical composition comprising a compound represented by Formula (I):

##STR00001## wherein R.sup.1 is haloalkyl or non-aromatic carbocyclyl, R.sup.2 is a hydrogen atom or halogen, R.sup.3 is halogen, ring A is a group represented by the formula:

##STR00002## -L.sup.1- is —O—(CH.sub.2)—, —(CH.sub.2).sub.2—, or the like, R.sup.4 is alkyl or haloalkyl, and R.sup.5 is alkylcarbonyl or carbamoyl, or a pharmaceutically acceptable salt thereof.

Provided is a pharmaceutical composition for treating and/or preventing fatty liver disease, particularly nonalcoholic fatty liver disease, the pharmaceutical composition having an excellent ACC2-selective inhibitory action and having no side effects such as an increase in plasma triglyceride or a decrease in platelet concentration.

A pharmaceutical composition for treating and/or preventing fatty liver disease, the pharmaceutical composition comprising a compound represented by Formula (I):

##STR00001## wherein R.sup.1 is haloalkyl or non-aromatic carbocyclyl, R.sup.2 is a hydrogen atom or halogen, R.sup.3 is halogen, ring A is a group represented by the formula:

##STR00002## -L.sup.1- is —O—(CH.sub.2)—, —(CH.sub.2).sub.2—, or the like, R.sup.4 is alkyl or haloalkyl, and R.sup.5 is alkylcarbonyl or carbamoyl, or a pharmaceutically acceptable salt thereof.

Provided is a pharmaceutical composition for treating and/or preventing fatty liver disease, particularly nonalcoholic fatty liver disease, the pharmaceutical composition having an excellent ACC2-selective inhibitory action and having no side effects such as an increase in plasma triglyceride or a decrease in platelet concentration.

A pharmaceutical composition for treating and/or preventing fatty liver disease, the pharmaceutical composition comprising a compound represented by Formula (I):

##STR00001## wherein R.sup.1 is haloalkyl or non-aromatic carbocyclyl, R.sup.2 is a hydrogen atom or halogen, R.sup.3 is halogen, ring A is a group represented by the formula:

##STR00002## -L.sup.1- is —O—(CH.sub.2)—, —(CH.sub.2).sub.2—, or the like, R.sup.4 is alkyl or haloalkyl, and R.sup.5 is alkylcarbonyl or carbamoyl, or a pharmaceutically acceptable salt thereof.

Disclosed are methods for treating a myelodyspastic syndrome (MDS) and/or an acute myeloid leukemia (AML) in an individual in need thereof. Further disclosed are compositions for use in the disclosed methods, used for treating a myelodyspastic syndrome (MDS) and/or an acute myeloid leukemia (AML) in an individual in need thereof.

Disclosed are methods for treating a myelodyspastic syndrome (MDS) and/or an acute myeloid leukemia (AML) in an individual in need thereof. Further disclosed are compositions for use in the disclosed methods, used for treating a myelodyspastic syndrome (MDS) and/or an acute myeloid leukemia (AML) in an individual in need thereof.

The present invention describes the use of a 5HT3-antagonist, in combination with a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to reduce adverse effects and to facilitate the neuroprotective treatment of a patient suffering from a synucleinopathic disorder to enable a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose without the dose-limiting adverse effects caused by pramipexole when administered alone.

The present invention describes the use of a 5HT3-antagonist, in combination with a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to reduce adverse effects and to facilitate the neuroprotective treatment of a patient suffering from a synucleinopathic disorder to enable a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose without the dose-limiting adverse effects caused by pramipexole when administered alone.

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.